SEC Form 4 · accession 0001209191-15-009380
CELGENE CORP /DE/ · CELG
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Scott Andrew Smith
Officer — See Remarks
Period of report
Feb 2, 2015
Accepted (ET)
Feb 4, 2015 · 4:09 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000816284
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F2,F1 | $118.57 | Feb 2, 2015 | A | 5,000 | A | — | Feb 2, 2025 | Common Stock | 5,000 | 5,000 | D |
Explanation of responses
- F1Option is immediately exercisable and will vest in four equal annual installments commencing on February 2, 2016.
- F2The option was issued pursuant to the Celgene Corporation 2008 Stock Incentive Plan (Amended and Restated as of April 17, 2013).
Remarks
President Inflammation & Immunology